Bronchogen

Overview

Bronchogen, also referred to as chonluten in some Russian literature, is a synthetic tetrapeptide of sequence Ala-Glu-Asp-Leu (AEDL) belonging to the family of short peptide "bioregulators" developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. It is marketed as a research compound intended for study of bronchial epithelial biology.

Khavinson-class peptides are short (typically 2–4 amino acids) sequences derived from chemical analysis of peptide extracts of specific mammalian organs. Each peptide is proposed to carry a tissue-specific regulatory signature. Bronchogen is the bronchial counterpart within this family, alongside peptides directed at the pineal gland (Epithalon), thymus (Crystagen), cartilage (Cartalax), and others.

Bronchogen is a research compound and is not approved as a pharmaceutical outside of specific Russian bioregulator preparations.

Structure / Chemistry

• Sequence: H-Ala-Glu-Asp-Leu-OH
• Three-letter notation: Ala-Glu-Asp-Leu
• Molecular formula: C19H32N4O9
• Molecular weight: approximately 460 g/mol
• Class: Linear unmodified tetrapeptide

The AEDL sequence differs from Epithalon (AEDG) in substituting leucine for glycine at the C-terminus. This change introduces a hydrophobic side chain that subtly alters solubility and may influence tissue partitioning. The peptide carries free N-terminal amine and C-terminal carboxylate groups.

Mechanism of Action

Within the Khavinson bioregulator research model, Bronchogen is proposed to exert tissue-selective effects on bronchial epithelium:

• Direct interaction with DNA regulatory sequences in bronchial epithelial cells, according to the Khavinson-group model of short-peptide gene regulation
• Modulation of gene expression patterns associated with ciliated cell differentiation, surfactant-related protein synthesis, and antioxidant defense
• Proposed effects on chronic obstructive airway pathology in aged or injured bronchial tissue
• Indirect immune modulation through interaction with bronchus-associated lymphoid tissue

The direct-DNA-binding model remains a signature claim of the Khavinson research tradition and has received limited independent validation outside that tradition. Mainstream molecular biology typically favors receptor- or transporter-mediated explanations for peptide bioactivity, and more work is needed to fully resolve Bronchogen's mechanism.

Research Summary

Peer-reviewed Western-journal coverage of AEDL-specific studies is limited; much of the literature appears in Russian bioregulator journals.

Pharmacokinetics

Formal pharmacokinetic studies of Bronchogen are sparse in mainstream publications. As an unmodified tetrapeptide, AEDL is expected to have a very short plasma half-life (minutes) due to rapid proteolysis and renal clearance, consistent with related Khavinson peptides.

Research-grade use typically employs subcutaneous, intranasal, or inhaled administration. The Khavinson model posits tissue-selective partitioning that concentrates activity at the proposed target organ even at low systemic concentrations. Elimination is through proteolytic degradation to free amino acids and their typical catabolic pathways.

Common Discussion Topics

• Position within the Khavinson peptide bioregulator family
• Evidence base in Russian vs Western peer-reviewed literature
• Plausibility of direct DNA-binding mechanism in short tetrapeptides
• Overlap with conventional respiratory research peptides
• Standards for research-grade purity and authentication

Related Compounds

• Epithalon — pineal Khavinson tetrapeptide
• Crystagen — thymus Khavinson tetrapeptide
• Cartalax — cartilage Khavinson tetrapeptide
• Thymalin — thymic peptide preparation
• Cerebrolysin — multi-peptide neurotrophic preparation

Educational information only. Bronchogen is a research peptide with limited independent clinical validation. This article does not constitute medical or dosing advice.